BNP Paribas Asset Management
AKRO

BNP Paribas Asset Management’s Akero Therapeutics AKRO Stock Holding History

BNP Paribas Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-504
Closed -$24K – 2266
2025
Q3 		$24K Buy
504
+12
+2% +$581 ﹤0.01% 1307
2025
Q2 		$26K Buy
+492
New +$22.4K ﹤0.01% 1394

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BNP Paribas Asset Management's AKRO Position: Q4 2025 in Review

BNP Paribas Asset Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 504 shares — an estimated $24K sold.

BNP Paribas Asset Management first reported a position in AKRO in Q2 2025 and held it in 2 quarters. The position peaked at $26K in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • BNP Paribas Asset Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • BNP Paribas Asset Management sold 504 Akero Therapeutics shares in Q4 2025, an estimated $24K.
  • BNP Paribas Asset Management first reported a position in Akero Therapeutics in Q2 2025 and held it in 2 quarters.
  • BNP Paribas Asset Management's Akero Therapeutics position peaked at $26K in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on BNP Paribas Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.